“Finn is an exceptional lawyer who brings an invaluable skillset to our practice as our clients continue to tap the public markets to grow their businesses,” said Mitch Bloom, chair of Goodwin’s Life Sciences practice. “His extensive industry experience in the life sciences and technology industries is well aligned with our integrated platform at the intersection of capital and innovation. We are delighted to have Finn on our global team.”
Murphy focuses his practice on the representation of issuers and underwriters in public and private securities offerings and advises on corporate governance, SEC reporting, and disclosure obligations. Finn has experience with a wide variety of capital markets transactions involving U.S. and non-U.S. issuers, including IPOs and other equity offerings, convertible offerings, and investment-grade and high-yield debt financings.
Goodwin’s Capital Markets practice is routinely recognized for excellence around the world by Chambers, The Legal 500, and IFLR1000. Bloomberg's full year 2021 capital markets league tables highly rank Goodwin for its ability to advise clients on equity linked capital markets transactions on behalf of U.S. underwriters, as well as for U.S. IPOs and equity offerings, and global equity, equity linked, and rights transactions on behalf of underwriters.
U.S. News — Best Lawyers' 2022 edition named Goodwin the Biotechnology Law Firm of the Year for the seventh time in the last eight years. LMG Life Sciences named Goodwin Firm of the Year in the corporate and intellectual property categories, and distinguished Goodwin as a lifecycle firm.